

Anna S Berghoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7548192/publications.pdf>

Version: 2024-02-01

25
papers

1,111
citations

759233

12
h-index

839539

18
g-index

25
all docs

25
docs citations

25
times ranked

2264
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203. | 30.7 | 359 |
| 2 | Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolimmunology</i> , 2016, 5, e1057388. | 4.6 | 239 |
| 3 | CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413. | 7.7 | 116 |
| 4 | Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852. | 1.6 | 93 |
| 5 | New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). <i>ESMO Open</i> , 2019, 4, e000629. | 4.5 | 78 |
| 6 | Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. <i>JAMA Oncology</i> , 2022, 8, 106. | 7.1 | 53 |
| 7 | SARS-CoV-2 Testing in Patients With Cancer Treated at a Tertiary Care Hospital During the COVID-19 Pandemic. <i>Journal of Clinical Oncology</i> , 2020, 38, 3547-3554. | 1.6 | 40 |
| 8 | Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study. <i>European Journal of Cancer</i> , 2022, 165, 184-194. | 2.8 | 29 |
| 9 | Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198. | 2.9 | 25 |
| 10 | Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210962. | 3.2 | 21 |
| 11 | Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863. | 4.5 | 17 |
| 12 | Awareness of predatory journals and open access among medical oncologists: results of an online survey. <i>ESMO Open</i> , 2019, 4, e000580. | 4.5 | 15 |
| 13 | Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650. | 4.2 | 10 |
| 14 | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. <i>ESMO Open</i> , 2020, 5, e000647. | 4.5 | 4 |
| 15 | Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. <i>ESMO Open</i> , 2020, 5, e000880. | 4.5 | 4 |
| 16 | How I treat anaplastic glioma without 1p/19q codeletion. <i>ESMO Open</i> , 2019, 4, e000534. | 4.5 | 3 |
| 17 | SARS-CoV-2 screening in cancer outpatients during the second wave of the COVID-19 pandemic. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 909-914. | 1.9 | 2 |
| 18 | SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria. <i>Wiener Klinische Wochenschrift</i> , 2022, , 1. | 1.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111. | 1.2 | 1 |
| 20 | IMMU-26. VISUALIZING TUMOR CELL - LYMPHOCYTE INTERACTIONS IN THE BRAIN METASTATIC CASCADE USING IN VIVO TWO PHOTON MICROSCOPY. <i>Neuro-Oncology</i> , 2018, 20, vi126-vi127. | 1.2 | 0 |
| 21 | CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY. <i>Neuro-Oncology</i> , 2018, 20, vi59-vi59. | 1.2 | 0 |
| 22 | MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi155-vi155. | 1.2 | 0 |
| 23 | SURG-13. EVALUATION OF 5-ALA FLUORESCENCE IN BRAIN METASTASES OF VARIOUS PRIMARY TUMORS: A MULTICENTER STUDY WITH EXPERIENCE IN 157 CASES. <i>Neuro-Oncology Advances</i> , 2019, 1, i33-i33. | 0.7 | 0 |
| 24 | NIMG-09. DETECTION OF ASYMPTOMATIC MALIGNANT LESIONS BY [18F]FDG PET/MRI IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2021, 23, vi129-vi129. | 1.2 | 0 |
| 25 | PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124. | 1.2 | 0 |